Swati AG is a 100% subsidiary of Swati Spentose Pvt. Ltd. (SSPL) which is a part of a 50 year old group based in Mumbai, India. Swati AG was set up in the canton of Zug in 2019, with a vision to engage with European innovation for the world and facilitate access to the Indian economy. We aim to do business with all the regulated markets like EU, USA, Canada, Australia and other strategic markets which needs the USFDA scientific platform. The company’s flagship molecule is Pentosan Polysulphate sodium knows as PPS. The company is currently using PPS for treating Interstitial cystitis (I.C)/Bladder Pain Syndrome (BPS). BPS is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area, combined with lower urinary tract symptoms which have lasted for more than 6 weeks, without having an infection or other clear causes. The parent company SSPL is the first company in the world to launch a generic version of PPS for neglected disease, I.C. for human as well as veterinary use.